Novel Endomorphin Analogs Are More Potent and Longer-Lasting Analgesics in Neuropathic, Inflammatory, Postoperative, and Visceral Pain Relative to Morphine

J Pain. 2017 Dec;18(12):1526-1541. doi: 10.1016/j.jpain.2017.08.007. Epub 2017 Sep 20.

Abstract

Activation of the mu-opioid receptor provides the gold standard for pain relief, but most opioids used clinically have adverse effects that have contributed to an epidemic of overdose deaths. We recently characterized mu-opioid receptor selective endomorphin (EM) analogs that provide potent antinociception with reduction or absence of a number of side effects of traditionally prescribed opioids including abuse liability, respiratory depression, motor impairment, tolerance, and inflammation. The current study explores the effectiveness of these EM analogs relative to morphine in four major pain models by intrathecal as well as intravenous administration in male Sprague Dawley rats and subcutaneous administration in male CD-1 mice. In the spared nerve injury model of neuropathic pain, mechanical allodynia and mechanical hyperalgesia were assessed with von Frey and Randall-Selitto tests, respectively. In the paw incision model of postoperative pain, von Frey testing was used to assess mechanical allodynia and thermal hyperalgesia was evaluated with Hargreaves testing. In the Complete Freund's Adjuvant model of inflammatory pain, thermal hyperalgesia was assessed using Hargreaves testing. In CD-1 mice, visceral pain was assessed with the acetic acid writhing test. In all cases, EM analogs had equal or greater potency and longer duration of action relative to morphine. The data suggest that EM analogs, particularly analog 4 (ZH853), could provide effective therapy for a diverse spectrum of pain conditions with low risk of adverse side effects compared with currently used opioids such as morphine.

Perspective: Novel EM analogs show equal or greater potency and effectiveness relative to morphine in multiple pain models. Together with substantially reduced side effects, including abuse liability, the compounds show promise for addressing the critical need for effective pain relief as well as reducing the opioid overdose epidemic.

Keywords: Pre-clinical pain models; endomorphin analogs; inflammatory pain; morphine; neuropathic pain; postoperative pain; visceral pain.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Disease Models, Animal
  • Hyperalgesia / drug therapy*
  • Inflammation / complications
  • Injections, Intravenous
  • Injections, Spinal
  • Male
  • Mice
  • Morphine / pharmacology*
  • Neuralgia / drug therapy*
  • Nociceptive Pain / drug therapy*
  • Nociceptive Pain / etiology
  • Oligopeptides / analysis*
  • Pain, Postoperative / drug therapy*
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Visceral Pain / drug therapy*

Substances

  • Analgesics, Opioid
  • Oligopeptides
  • Peptides, Cyclic
  • Tyr-c(Lys-Trp-Phe-Glu)-Gly-NH2
  • endomorphin 1
  • endomorphin 2
  • Morphine